Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) – Pipeline Review, H2 2017’, provides in depth analysis on Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas under Central Nervous System, Cardiovascular, Ophthalmology and Respiratory development targeting Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)

The report reviews Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Arrien Pharmaceuticals LLC

D. Western Therapeutics Institute Inc

Denali Therapeutics Inc

H. Lundbeck AS

Ionis Pharmaceuticals Inc

Lead Discovery Center GmbH

Merck & Co Inc

Oncodesign SA

Origenis GmbH

Pfizer Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC

2.7.11.1) Overview

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC

2.7.11.1) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC

2.7.11.1) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC

2.7.11.1) Companies Involved in Therapeutics Development

Arrien Pharmaceuticals LLC

D. Western Therapeutics Institute Inc

Denali Therapeutics Inc

H. Lundbeck AS

Ionis Pharmaceuticals Inc

Lead Discovery Center GmbH

Merck & Co Inc

Oncodesign SA

Origenis GmbH

Pfizer Inc

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC

2.7.11.1) Drug Profiles

Antisense Oligonucleotides to Inhibit LRRK2 for Parkinson's Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARN-1104 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DNL-151 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DNL-201 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GNE-7915 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

H-1337 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ODS-2005294 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06447475 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit LRRK-2 for Parkinson's Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LRRK-2 for Parkinson's Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LRRK2 for Neurodegenerative Diseases Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LRRK2 for Neurodegenerative Diseases and Parkinson's Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LRRK2 for Parkinson's Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LRRK2 for Parkinson's Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LRRK2 for Parkinson's Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LRRK2 for Parkinson's Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SR-9444 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC

2.7.11.1) Dormant Products

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC

2.7.11.1) Product Development Milestones

Featured News & Press Releases

Dec 20, 2017: Denali Therapeutics Provides Update on DNL151

Dec 20, 2017: Denali Therapeutics Announces Advancement and Expansion of Its LRRK2 Inhibitor Clinical Program for Parkinson's Disease

May 23, 2017: Origenis Announces Patent Grants for Lead Small Molecule LRRK2 Inhibitors for Treatment of Neurodegenerative and Inflammatory Diseases

May 30, 2016: Oncodesign is granted new patent protecting key molecules generated from its Nanocyclix technology platform for next generation kinase inhibitors

Oct 21, 2015: Oncodesign Presents Novel LRRK2 Inhibitor Jointly Discovered with Ipsen at the 2015 Neurosciences Meeting in Chicago

Sep 09, 2014: Arrien Pharmaceuticals announced that the U.S. Patent and Trademark Office has issued U.S. Patents No. 8,791,112 B2

Aug 16, 2012: Arrien Pharma’s ORS-1104 Advances Into Investigational New Drug Enabling Stage

May 05, 2012: Arrien Pharma Provides Update On ORS-1104 For Treatment Of Parkinson’s Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indication, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Arrien Pharmaceuticals LLC, H2 2017

Pipeline by D. Western Therapeutics Institute Inc, H2 2017

Pipeline by Denali Therapeutics Inc, H2 2017

Pipeline by H. Lundbeck AS, H2 2017

Pipeline by Ionis Pharmaceuticals Inc, H2 2017

Pipeline by Lead Discovery Center GmbH, H2 2017

Pipeline by Merck & Co Inc, H2 2017

Pipeline by Oncodesign SA, H2 2017

Pipeline by Origenis GmbH, H2 2017

Pipeline by Pfizer Inc, H2 2017

Dormant Projects, H2 2017

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports